Eragny-sur-Oise (France), July 22, 2015
SAFE ORTHOPAEDICS (Euronext: FR0012452746 – SAFOR), a company developing and marketing an innovative range of sterile implants combined with their single-use surgical instruments, today announces the positive outcomes of a retrospective clinical study carried out by Dr. Gregory Lanford, neurosurgeon at St.Thomas Hospital for Specialty Surgery, Nashville, TN.
Dr. Lanford said:
“Safe Orthopaedics’ Sterispine™ is a cost-effective system that negates the need for sterilization and potentially lowers the infection rate by mitigating risks for cross-contamination. The instruments are easy to use by any surgeon experienced in pedicle screw fixation.”
A total of 45 patients were operated on completing an instrumented lumbar fusion via an open or percutaneous approach using Sterispine kits by the author between July of 2013 and January of 2015. A 3 to 12 months follow-up period has been performed for each patient with plain radiograph at 1, 3, 6 and 12 months.
No cases of infection nor morbidity or mortality were reported while the infection rate for instrumented lumbar fusion is commonly found in the literature at 3-6% with a peak at two weeks post-op.
Tim Nye, Safe Orthopaedics US Vice President, added:
“This study is an important milestone as it highlights the potential benefits of using Safe Orthopaedics products. We are very thankful to Dr. Lanford for this important work.”